We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Oncology

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials

MedXY Editorial Team•Oct 4, 2025•Oncology
overall survivalprostate cancerstatins

Highlight

– Statin exposure correlates with significantly longer overall survival (OS) in patients with advanced prostate cancer treated with apalutamide.
– No survival benefit was observed with statin use in patients receiving placebo.
– Statin-exposed patients had increased risk of grade 3 or higher cardiac adverse events (AEs), likely reflecting preexisting cardiovascular disease.
– These findings come from a comprehensive cohort analysis of two large phase 3 randomized trials, TITAN and SPARTAN.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Advancing Treatment in De Novo BCR::ABL1+ Acute Myeloid Leukemia: The Impact of Combining Intensive Chemotherapy with Tyrosine Kinase InhibitorsThe addition of tyrosine kinase inhibitors to intensive chemotherapy markedly improves remission rates and overall survival in patients with de novo BCR::ABL1+ acute myeloid leukemia, suggesting a new standard of care approach.Sep 24, 2026Lymphovascular Invasion as an Independent Prognostic Marker in Laryngeal Squamous Cell Carcinoma: Insights from a National Cohort StudyLymphovascular invasion independently predicts worse overall survival in surgically treated laryngeal squamous cell carcinoma, influencing postoperative risk stratification and adjuvant therapy decisions.Sep 23, 2026A Synopsis of the 2025 VA/DoD Lipid Management Guideline: What Clinicians Need to KnowConcise review of the 2025 VA/DoD lipid guideline: new risk tool (PREVENT), CAC and one-time Lp(a) for risk refinement, statins for selected primary prevention groups (including people with HIV), and intensified combination therapy for verySep 19, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study
This study evaluates how the number and positivity of lymph nodes affect survival outcomes in over 2,000 patients with stage I–III favorable histology Wilms tumor, underscoring the need for standardized lymph node sampling in surgical stagi
Sep 13, 2026
Specialist Cardiovascular Referral Enhances Cholesterol Management in Prostate Cancer Patients: Insights from a Global Randomized TrialA randomized clinical trial demonstrates that routine cardiovascular specialist referral for prostate cancer patients improves cholesterol control but does not reduce major cardiovascular events over nearly 6 years.Sep 1, 2026
Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final AnalysisThe MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patientsAug 26, 2026